article thumbnail

Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation

pharmaphorum

Regulators in the US and UK are reviewing data from another vaccine from Novavax. Sanofi’s shot combines the recombinant DNA technology it uses to make flue vaccines with the adjuvants GSK uses to boost the immune system with its jabs.